Correction to: A roadmap for clinical trials in MASH-related compensated cirrhosis (Nature Reviews Gastroenterology & Hepatology, (2024), 10.1038/s41575-024-00955-8)

Juan M. Pericàs; Quentin M. Anstee; Salvador Augustin; Ramón Bataller; Annalisa Berzigotti; Andreea Ciudin; Sven Francque; Juan G. Abraldes; Virginia Hernández-Gea; Mònica Pons; Thomas Reiberger; Ian A. Rowe; Peter Rydqvist; Elmer Schabel; Frank Tacke; Emmanuel A. Tsochatzis; Joan Genescà

doi:10.1038/s41575-024-00976-3

Correction to: A roadmap for clinical trials in MASH-related compensated cirrhosis (Nature Reviews Gastroenterology & Hepatology, (2024), 10.1038/s41575-024-00955-8)

Juan M. Pericàs, Quentin M. Anstee, Salvador Augustin, Ramón Bataller, Annalisa Berzigotti, Andreea Ciudin, Sven Francque, Juan G. Abraldes, Virginia Hernández-Gea, Mònica Pons, Thomas Reiberger, Ian A. Rowe, Peter Rydqvist, Elmer Schabel, Frank Tacke, Emmanuel A. Tsochatzis, Joan Genescà

Research output: Contribution to journal › Comment/debate

Abstract

Correction to: Nature Reviews Gastroenterology & Hepatologyhttps://doi.org/10.1038/s41575-024-00955-8, published online 17 July 2024. In the version of the article initially published, the reference Chalasani, N. et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterol. 158 1334–1345 (2020) was missing and has now been added as ref. 111 in the second paragraph of the “HVPG as a surrogate end point” section. Additionally, in the second paragraph of the “Current scenario of clinical trials in MASH” section, the sentence “NAVIGATE (NCT04365868; 357 participants) was a phase IIb–III trial…” has been corrected to “NAVIGATE (NCT04365868; 357 participants) is a phase IIb–III trial…”. These corrections have been made to the HTML and PDF versions of the article.

Original language	English
Journal	Nature Reviews Gastroenterology and Hepatology
DOIs	https://doi.org/10.1038/s41575-024-00976-3
State	Accepted/In press - 2024
Externally published	Yes

Access to Document

10.1038/s41575-024-00976-3

Cite this

Pericàs, J. M., Anstee, Q. M., Augustin, S., Bataller, R., Berzigotti, A., Ciudin, A., Francque, S., Abraldes, J. G., Hernández-Gea, V., Pons, M., Reiberger, T., Rowe, I. A., Rydqvist, P., Schabel, E., Tacke, F., Tsochatzis, E. A., & Genescà, J. (Accepted/In press). Correction to: A roadmap for clinical trials in MASH-related compensated cirrhosis (Nature Reviews Gastroenterology & Hepatology, (2024), 10.1038/s41575-024-00955-8). Nature Reviews Gastroenterology and Hepatology. https://doi.org/10.1038/s41575-024-00976-3

@article{524abbff1b56450db77e17fa74faeaeb,

title = "Correction to: A roadmap for clinical trials in MASH-related compensated cirrhosis (Nature Reviews Gastroenterology & Hepatology, (2024), 10.1038/s41575-024-00955-8)",

abstract = "Correction to: Nature Reviews Gastroenterology & Hepatologyhttps://doi.org/10.1038/s41575-024-00955-8, published online 17 July 2024. In the version of the article initially published, the reference Chalasani, N. et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterol. 158 1334–1345 (2020) was missing and has now been added as ref. 111 in the second paragraph of the “HVPG as a surrogate end point” section. Additionally, in the second paragraph of the “Current scenario of clinical trials in MASH” section, the sentence “NAVIGATE (NCT04365868; 357 participants) was a phase IIb–III trial…” has been corrected to “NAVIGATE (NCT04365868; 357 participants) is a phase IIb–III trial…”. These corrections have been made to the HTML and PDF versions of the article.",

author = "Peric{\`a}s, {Juan M.} and Anstee, {Quentin M.} and Salvador Augustin and Ram{\'o}n Bataller and Annalisa Berzigotti and Andreea Ciudin and Sven Francque and Abraldes, {Juan G.} and Virginia Hern{\'a}ndez-Gea and M{\`o}nica Pons and Thomas Reiberger and Rowe, {Ian A.} and Peter Rydqvist and Elmer Schabel and Frank Tacke and Tsochatzis, {Emmanuel A.} and Joan Genesc{\`a}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Limited 2024.",

year = "2024",

doi = "10.1038/s41575-024-00976-3",

language = "English",

journal = "Nature Reviews Gastroenterology and Hepatology",

issn = "1759-5045",

publisher = "Nature Publishing Group",

}

Pericàs, JM, Anstee, QM, Augustin, S, Bataller, R, Berzigotti, A, Ciudin, A, Francque, S, Abraldes, JG, Hernández-Gea, V, Pons, M, Reiberger, T, Rowe, IA, Rydqvist, P, Schabel, E, Tacke, F, Tsochatzis, EA & Genescà, J 2024, 'Correction to: A roadmap for clinical trials in MASH-related compensated cirrhosis (Nature Reviews Gastroenterology & Hepatology, (2024), 10.1038/s41575-024-00955-8)', Nature Reviews Gastroenterology and Hepatology. https://doi.org/10.1038/s41575-024-00976-3

TY - JOUR

T1 - Correction to

T2 - A roadmap for clinical trials in MASH-related compensated cirrhosis (Nature Reviews Gastroenterology & Hepatology, (2024), 10.1038/s41575-024-00955-8)

AU - Pericàs, Juan M.

AU - Anstee, Quentin M.

AU - Augustin, Salvador

AU - Bataller, Ramón

AU - Berzigotti, Annalisa

AU - Ciudin, Andreea

AU - Francque, Sven

AU - Abraldes, Juan G.

AU - Hernández-Gea, Virginia

AU - Pons, Mònica

AU - Reiberger, Thomas

AU - Rowe, Ian A.

AU - Rydqvist, Peter

AU - Schabel, Elmer

AU - Tacke, Frank

AU - Tsochatzis, Emmanuel A.

AU - Genescà, Joan

PY - 2024

Y1 - 2024

N2 - Correction to: Nature Reviews Gastroenterology & Hepatologyhttps://doi.org/10.1038/s41575-024-00955-8, published online 17 July 2024. In the version of the article initially published, the reference Chalasani, N. et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterol. 158 1334–1345 (2020) was missing and has now been added as ref. 111 in the second paragraph of the “HVPG as a surrogate end point” section. Additionally, in the second paragraph of the “Current scenario of clinical trials in MASH” section, the sentence “NAVIGATE (NCT04365868; 357 participants) was a phase IIb–III trial…” has been corrected to “NAVIGATE (NCT04365868; 357 participants) is a phase IIb–III trial…”. These corrections have been made to the HTML and PDF versions of the article.

AB - Correction to: Nature Reviews Gastroenterology & Hepatologyhttps://doi.org/10.1038/s41575-024-00955-8, published online 17 July 2024. In the version of the article initially published, the reference Chalasani, N. et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterol. 158 1334–1345 (2020) was missing and has now been added as ref. 111 in the second paragraph of the “HVPG as a surrogate end point” section. Additionally, in the second paragraph of the “Current scenario of clinical trials in MASH” section, the sentence “NAVIGATE (NCT04365868; 357 participants) was a phase IIb–III trial…” has been corrected to “NAVIGATE (NCT04365868; 357 participants) is a phase IIb–III trial…”. These corrections have been made to the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85200410102&partnerID=8YFLogxK

U2 - 10.1038/s41575-024-00976-3

DO - 10.1038/s41575-024-00976-3

M3 - Comment/debate

AN - SCOPUS:85200410102

SN - 1759-5045

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

ER -

Correction to: A roadmap for clinical trials in MASH-related compensated cirrhosis (Nature Reviews Gastroenterology & Hepatology, (2024), 10.1038/s41575-024-00955-8)

Abstract

Access to Document

Fingerprint

Cite this